CVS Health is a vertically integrated healthcare behemoth spanning health insurance (Aetna), pharmacy benefit management (Caremark), and retail pharmacy. While its scale provides robust and defensive cash flow generation, near-term headwinds from Medicare Advantage rates and retail margin compression weigh on profitability. Fair value range: low $62.5, high $112, with mid-point at $86.8.
Currently screens above fair value, so patience matters more than entry speed.
Fair value
$87
Margin of safety
-9.6%
Confidence
88/100
Moat
6.5/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$95.15Price
Low $62.46
Mid $86.81
High $112.2
CVS Health is a vertically integrated healthcare behemoth spanning health insurance (Aetna), pharmacy benefit management (Caremark), and retail pharmacy. While its scale provides robust and defensive cash flow generation, near-term headwinds from Medicare Advantage rates and retail margin compression weigh on profitability.
Vertical integration creating a closed-loop
Vertical integration creating a closed-loop value-based care model.
Immense scale in Pharmacy Benefit
Immense scale in Pharmacy Benefit Management via Caremark.
Cycle upside
Healthcare utilization normalizes post-pandemic while value-based care assets (Oak Street, Signify) mature and expand consolidated margins.
CVS (CVS)'s intrinsic value is triangulated from discounted earnings at two cost-of-equity levels (strict CAPM with raw beta, moderate with adjusted beta), with owner earnings used as a floor for high-growth names.
Each model produces a per-share value; the composite range comes from a weighted blend driven by the archetype's model-applicability matrix. Cost of equity, terminal growth, and the deceleration curve are documented in the assumption ledger.
EPS-based models are discounted at cost of equity; FCFF models use WACC and then subtract net debt to bridge enterprise value to equity value. Each model is labelled with its discount-rate convention so the reader can verify the bridge.
Owner earnings (Buffett's definition) is net income plus depreciation and amortization minus maintenance capex. We do not subtract stock-based compensation again because net income already includes it; dilution is tracked separately via share-count growth.
FAQ
CVS — frequently asked questions
Based on our latest analysis, CVS screens modestly overvalued. The current price is $95.2 versus a composite fair-value midpoint of $86.8 (range $62.5–$112), which implies roughly 8.8% downside to the midpoint.
Our composite fair-value range for CVS is $62.5–$112, with a midpoint of $86.8. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for CVS's archetype.
Our current rating for CVS is Hold with a confidence score of 88/100. Hold. Fair value is mathematically anchored at $86.81 due to vital downside FCFF penalizations. We recommend maintaining current positions given the defensive $7.8B cash-generation engine, but avoiding new capital deployment until valuation gaps close or MA headwinds tangibly recede. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for CVS are: Severe MA Rate Rebasing; Retail Pharmacy Collapse; Debt Deleveraging Failure. The single biggest risk is Severe MA Rate Rebasing: Persistent medical cost inflation combines with unfavorable Medicare Advantage reimbursement updates, compressing insurance margins structurally above 88% MLR without offsetting premium increases.
Our current rating for CVS is Hold, issued with a confidence score of 88/100 and a moat score of 6.5/10. The rating reflects the composite fair-value range ($62.5–$112) versus the current price of $95.2.
CVS is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for CVS.